Quizartinib: FMSālike Tyrosine Kinase 3 (FLT 3) Inhibitor
Acute Myeloid Leukemia (AML)Ā represents one of the largest hematologic cancer populations with one of the worst survival rates. Patients with r/r...
297 Views
Celltrion Healthcare IPO - Early Review on Key Issues
Celltrion Healthcare, which isĀ Celltrion (068270)ās overseas sales and marketing unit, submitted the application for preliminary screening for...
422 Views
'Cures Act', Halol Plant FDA Inspection and a Russian Acquisition.
We continue to be bullish on Sun Pharmaceutical Indus (SUNP IN) after the recent news of progress in passing the '21st century Cures Act' in the...
454 Views
Long Position with Upcoming Catalysts
We expect the complete response letter (CRL) for Andexanet Alfa to be resolved in 2017 and the drug to be launched successfully in the U.S. market....
522 Views
One World, Two Stories
Celltrion's management continues to make very optimistic projections about Remsima's US sales in 2017 despite regulatory hurdles that will limit...
340 Views